Urmăriți
Mario Eisenberger
Mario Eisenberger
Professor of Oncology,Johns Hopkins University
Adresă de e-mail confirmată pe jhmi.edu
Titlu
Citat de
Citat de
Anul
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ...
New England Journal of Medicine 351 (15), 1502-1512, 2004
70042004
Mortality results from a randomized prostate-cancer screening trial
GL Andriole, ED Crawford, RL Grubb III, SS Buys, D Chia, TR Church, ...
New England journal of medicine 360 (13), 1310-1319, 2009
38682009
Natural history of progression after PSA elevation following radical prostatectomy
CR Pound, AW Partin, MA Eisenberger, DW Chan, JD Pearson, PC Walsh
Jama 281 (17), 1591-1597, 1999
36741999
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ...
New England Journal of Medicine 373 (8), 737-746, 2015
26642015
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
26582014
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
23392008
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
ED Crawford, MA Eisenberger, DG McLeod, JT Spaulding, R Benson, ...
New England Journal of Medicine 321 (7), 419-424, 1989
18771989
Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland, EB Humphreys, LA Mangold, M Eisenberger, FJ Dorey, ...
Jama 294 (4), 433-439, 2005
15702005
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock
Journal of Clinical Oncology 26 (2), 242-245, 2008
14282008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock
Journal of Clinical Oncology 26 (2), 242-245, 2008
14282008
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
MA Eisenberger, BA Blumenstein, ED Crawford, G Miller, DG McLeod, ...
New England Journal of Medicine 339 (15), 1036-1042, 1998
11361998
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11271999
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ...
Journal of Clinical Oncology 36 (11), 1080, 2018
8172018
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
JB Nelson, SP Hedican, DJ George, AH Reddi, S Piantadosi, ...
Nature medicine 1 (9), 944-949, 1995
7631995
Cancer-related fatigue, version 2.2015
AM Berger, K Mooney, A Alvarez-Perez, WS Breitbart, KM Carpenter, ...
Journal of the National Comprehensive Cancer Network 13 (8), 1012-1039, 2015
7412015
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ...
Nature medicine 15 (5), 559-565, 2009
7202009
NCCN Practice Guidelines for Cancer-Related Fatigue.
V Mock, A Atkinson, A Barsevick, D Cella, B Cimprich, C Cleeland, ...
Oncology (Williston Park, NY) 14 (11A), 151-161, 2000
6922000
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ...
JAMA oncology 6 (5), 650-659, 2020
6782020
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
6552015
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ...
Molecular imaging and biology 17, 565-574, 2015
4592015
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20